bioMérieux and Biocartis Sign Strategic Partnership in Molecular Diagnostics

Co-development of assays and co-distribution of a fully integrated molecular platform due for launch in 2012

09-Nov-2010 - France

bioMérieux and Biocartis announced that they have entered into a strategic agreement to co-develop assays on Biocartis’ fully integrated molecular diagnostics system, which the two companies will co-distribute starting in 2012. Under the agreement, bioMérieux will have worldwide exclusive rights to develop and commercialize microbiology assays on the platform. It will also have access to the platform for certain oncology and theranostics assays. bioMérieux has taken a €9 million equity stake in Biocartis.

Biocartis has continued to successfully develop its molecular diagnostics platform, which was acquired from Philips earlier this year. The platform now fully integrates all the steps of a multiplexed molecular assay, from sample-in to data-out, in a sealed disposable cartridge, which avoids any contamination risk. Providing rapid results, the system is able to perform complex tests on a wide variety of samples, including oncology assays on tissue. The Biocartis platform does not require molecular biology experience or infrastructure with highly skilled technicians, and involves only 1-2 minutes hands-on time. Adapted to both small and large labs, the platform is fully scalable and allows random access use.

bioMérieux will enhance the Biocartis platform’s broad menu with an exclusive line of tests for healthcare-associated infections and sepsis. bioMérieux also plans to develop oncology and theranostics assays on the system.

https://www.analytica-world.com/en/news/125601/biomerieux-and-biocartis-sign-strategic-partnership-in-molecular-diagnostics.html